We use cookies to ensure that we give you the best experience on our website. By continuing to browse this repository, you give consent for essential cookies to be used. You can read more about our Privacy and Cookie Policy.

Durham Research Online
You are in:

Randomized, double-blind, placebo-controlled trial of intravenous (n-acetylcysteine, selenium, vitamin c) antioxidant therapy in severe acute pancreatitis.

Siriwardena, A. K. and Mason, J. M. and Balachandra, S. and Bagul, A. and Galloway, S. and Formela, L. and Hardman, J. G. and Jamdar, S. (2007) 'Randomized, double-blind, placebo-controlled trial of intravenous (n-acetylcysteine, selenium, vitamin c) antioxidant therapy in severe acute pancreatitis.', Gut., 56 (10). pp. 1439-1444.


Background: Based on equivocal clinical data, intravenous antioxidant therapy has been used for the treatment of severe acute pancreatitis. To date there is no randomised comparison of this therapy in severe acute pancreatitis. Methods: We conducted a randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in patients with predicted severe acute pancreatitis. Forty-three patients were enrolled from three hospitals in the Manchester (UK) area over the period June 2001 to November 2004. Randomisation stratified for APACHE-II score and hospital site, and delivered groups that were similar at baseline. Results: Relative serum levels of antioxidants rose while markers of oxidative stress fell in the active treatment group during the course of the trial. However, at 7 days, there was no statistically significant difference in the primary end point, organ dysfunction (antioxidant vs placebo: 32% vs 17%, p = 0.33) or any secondary end point of organ dysfunction or patient outcome. Conclusions: This study provides no evidence to justify continued use of n-acetylcysteine, selenium, vitamin C based antioxidant therapy in severe acute pancreatitis. In the context of any future trial design, careful consideration must be given to the risks raised by the greater trend towards adverse outcome in patients in the treatment arm of this study.

Item Type:Article
Full text:Full text not available from this repository.
Publisher Web site:
Record Created:13 May 2010 13:35
Last Modified:14 May 2010 11:05

Social bookmarking: del.icio.usConnoteaBibSonomyCiteULikeFacebookTwitterExport: EndNote, Zotero | BibTex
Look up in GoogleScholar | Find in a UK Library